menu ☰
menu ˟

FDA grants Imbruvica breakthrough designation for chronic GVHD

29 Jun 2016
The FDA today granted breakthrough therapy designation to ibrutinib as a monotherapy treatment for chronic graft-versus-host disease after failure of one or more lines of systemic therapy.The FDA also granted ibrutinib (Imbruvica; Pharmacyclics, Jans...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.